DOI: 10.4244/EIJV11SVA31

Is there a need for dedicated devices?

Joanna J. Wykrzykowska1*, MD, PhD; Maik J. Grundeken1, MD; Goran Stankovic2, MD, PhD; Carlo Di Mario3, MD, PhD

Abstract

Although the provisional approach is recommended over a systematic two-stent approach in bifurcation lesions, an a priori two-stent approach may be considered in certain specific anatomies in a minority of cases. Virtual bench test and intravascular imaging studies have provided essential insights into the technical aspects of bifurcation stenting and led to recommendations on how to optimise both the provisional and the two-stent strategies. Dedicated bifurcation stents may further optimise the procedural and clinical outcomes of both strategies. However, randomised data are sparse and more randomised trials are needed to provide evidence as to whether these dedicated devices will indeed improve procedural and clinical outcomes.

Introduction

Bifurcation lesions are encountered by interventional cardiologists in daily clinical practice in approximately 15%-20% of their percutaneous coronary intervention (PCI) cases. Multiple randomised trials, comparing a routine two-stent strategy with a provisional strategy (i.e., single stent in the main branch with additional side branch stenting only if indicated) have shown comparable efficacy outcomes (target vessel/lesion revascularisation rates) between the two treatment strategies1-3. However, the same trials also showed that the provisional strategy resulted in lower rates of periprocedural myocardial infarction (MI), less contrast use, lower X-ray doses and shorter procedural times1-3. Based on these data, the European Bifurcation Club (EBC) recommends the provisional strategy as the default strategy in the vast majority of bifurcation lesions4. However, there is also a consensus that it is reasonable to consider an upfront strategy with two stents if a large side branch is involved, if there is extensive side branch disease, if side branch occlusion is likely and/or if rewiring is anticipated to be difficult4,5. However, it remains a challenge to distinguish these more complex bifurcation lesions which are likely to require complex stenting procedures with multiple stents from the more “simple” bifurcation lesions which are likely to be adequately treated with the provisional approach. The “DEFINITION” study recently proposed a definition to define complex bifurcation lesions. However, this DEFINITION “score” needs to be validated in other bifurcation databases6. Multiple dedicated bifurcation devices have been developed over the last decade, to facilitate both the provisional (single) stent strategy and a more complex multi-stent approach. Most companies developing such devices have discontinued their efforts due to disappointing results and difficulties in improving the already excellent outcomes of the current bifurcation treatment using conventional newer-generation DES. In this paper we will discuss the current challenges of PCI of bifurcation lesions and how bifurcation devices may potentially improve procedural and clinical outcomes.

Why do we need dedicated devices to facilitate the provisional approach?

Virtual bench tests and intravascular imaging studies have provided essential insights into how to improve the provisional strategy, including rewiring through a distal stent cell7-10, main branch stent sizing according to the distal main branch4,11, and the use of the proximal optimisation technique (POT)12. However, challenges remain when using the provisional strategy. These include difficulties with side branch rewiring, proper stent sizing when there are large diameter differences between the proximal and distal main branch, and difficulties in performing final kissing balloon dilatation. Dedicated bifurcation stents may be helpful in overcoming these remaining challenges, further improving the provisional approach.

How dedicated stents potentially improve the provisional stenting strategy

DIFFICULTIES WITH REWIRING

Rewiring the side branch after main branch stent placement can sometimes be technically challenging and time-consuming. The Nile® stent (Minvasys, Gennevilliers, France) (Figure 1A) and the mother-daughter stent platforms (Advanced Bifurcation Systems [ABS], Los Angeles, CA, USA) may overcome this problem since both stents are advanced over two wires with access to both branches throughout the complete procedure. However, advancement over two wires may in its own right give rise to other technical problems such as wire twist, necessitating re-crossing13,14. These devices also tend to be more bulky and have worse crossing profiles than conventional stents. Another solution for difficulty in rewiring is provided by the BiOSS® dedicated bifurcation stent (Balton, Warsaw, Poland). This stent consists of proximal and distal stent parts, which are connected by only two connecting struts (Figure 1B). When the stent is positioned, it automatically “opens” itself towards the side branch because of its bending, especially when the proximal-to-distal main branch angle is relatively narrow15. This might theoretically simplify the rewiring into the side branch16. The conically shaped self-expanding nitinol Axxess™ stent (Biosensors Europe SA, Morges, Switzerland), which is placed in the proximal main branch up to the carina over a single wire, has a big advantage in that it does not cross one of the distal branches, leaving both daughter vessels freely accessible after placement (Figure 2)17-20.

Figure 1. Currently available dedicated bifurcation stents facilitating a provisional approach (according to “A” [main across side branch] of the MADS classification). A) The Nile stent. B) The BiOSS stent. C) The STENTYS stent.

Figure 2. The conically shaped self-expanding nitinol Axxess stent. A) An expanded Axxess stent. The three asterisks indicate the three distal markers, while the arrowhead indicates the single proximal marker. B) Placement of an Axxess stent in a silicone model. Adapted with permission from Dubois and Wijns17.

DIFFICULTIES IN SIZING APPROPRIATELY

Due to the fractal geometry of the coronary tree, proximal and distal diameters are per definition different21,22. Although sizing according to the distal diameter with additional POT did provide a solution to prevent carina shift while ensuring adequate proximal stent expansion and apposition when using conventional stents, it might be difficult to achieve optimal results when there is a large difference between the proximal and distal diameters. For this reason, the BiOSS stent is mounted on a stepped balloon with a larger proximal diameter than the distal part (in a ratio of 1.15-1.30)23. The STENTYS stent (STENTYS S.A., Paris, France) proposes a different solution to the problem (Figure 1C). The nitinol stent is deployed by retracting a sheath constraining the stent after which it expands itself until it reaches the vessel wall. The self-expanding stent adapts its calibre to the calibre of the distal and proximal vessel. The properties of the stent allow it to expand further beyond its indicated vessel diameters: the “medium-sized” STENTYS, for instance, suitable for vessels with diameters of 3.0-3.5 mm, expands up to 5.3 mm. The self-expanding Axxess stent has the obvious advantage that stent sizing can be performed for each bifurcation segment (i.e., proximal main, distal main and side branch) separately, with the additional advantage that the device fits the natural anatomy of the polygon of confluence of the bifurcation core (Figure 2)20.

DIFFICULTIES WITH FINAL KISSING BALLOON DILATATION

Side branch rewiring, needed to perform final kissing balloon dilatation, can be technically challenging and is not always possible. Furthermore, final kissing balloon dilatation itself might result in less favourable results in the proximal main branch, including stent strut malapposition and oval-shaped stent distortion when left uncorrected. A dedicated stent which does not deform during final kissing dilatation or does not need final kissing dilatation might not only simplify the procedure, but may also result in favourable outcomes. An example of such a device is the STENTYS stent. By disconnecting the interconnectors (i.e., the struts connecting subsequent hoops) using side branch dilatation, the stent part proximal to this disconnection flares open into the side branch ostium, while the stent distortions in the main branch which are usually seen after side branch dilatation are automatically corrected due to the memory shape of the stent. For the BiOSS stent, the stent cell opening in the connecting middle part might already provide a sufficient opening towards the side branch ostium without overhanging struts such that final kissing might be less essential in this device. When no additional stents are placed in the daughter vessels, the Axxess stent probably does not require final kissing balloon dilatation either.

Treatment of Medina 0,0,1 lesions

A real remaining challenge in bifurcation treatment is how properly to treat bifurcation lesions in which only the side branch ostium is involved (Medina 0,0,1). When performing ostial stenting, there is the potential risk of leaving a gap at the ostium if the stent is placed too distally, and there is also the risk of protruding stent struts if the stent is placed too proximally. In theory, adequate ostial coverage without protruding struts can only be achieved when the distal bifurcation angle is 90 degrees. Therefore, Brunel et al proposed the “inverted provisional T stenting”, placing a conventional DES from the side branch to the proximal main branch, leaving a large amount of metal in the non-diseased proximal main branch24. Although none of the current bifurcation devices has been specifically designed to treat Medina 0,0,1 bifurcation lesions, it has been proposed to treat these lesions using the Tryton stent (Tryton Medical, Inc., Durham, NC, USA) without an additional main branch stent (as in the Brunel technique, but then leaving only a minimal amount of metal). This has shown encouraging results in 12 patients25.

Why do we need dedicated devices to facilitate a two-stent approach?

Although no-one knows exactly in what percentage of patients with bifurcation lesions an a priori two-stent approach is the appropriate treatment, it is likely only to be a small minority. So, per definition, it will be a challenge to gain enough experience to master one or more of these complex two-stent techniques. Furthermore, all two-stent techniques have some drawbacks caused by the limitations of conventional stents, such as a limited expansion caused by the cell size through which the second stent is crossed in culotte, or the three layers of struts when using crush. Therefore, there is an unmet need for a dedicated stent which simplifies the two-stent approach. This stent should ideally fulfil the following criteria: the device should have a short learning curve, it should simplify the procedure (i.e., shorter procedural times, less contrast use), should adjust to the wide variety of bifurcation anatomies (including a wide range of distal bifurcation angles), should improve procedural success rates, should have a predictable acute result in the side branch, and should ensure long-term patency of the side branch without jeopardising the acute and long-term results in the main branch. Although a true “bifurcated” (Y-shaped) stent has always been “every interventionalist’s dream”26 because of its potential to solve all problems at once (Figure 3), such devices have turned out to be very bulky and, because they had to be advanced over two wires, there was a chance of wire wrap and misalignment. Such stents are currently no longer under development27-31.

Figure 3. The Medtronic Y-shaped bifurcation-dedicated stent (BDS) (Medtronic Inc., Santa Rosa, CA, USA). Although it is “every interventionalist’s dream” to have one device to solve all problems at once and to treat the entire bifurcation, such devices are no longer under development. From Lefèvre et al26 with permission.

How dedicated stents potentially improve a two-stent strategy

To the best of our knowledge, only two bifurcation stents facilitating the two-stent approach are currently under clinical investigation: the Tryton Side Branch Stent™ (Tryton Medical, Inc.) and the mother-daughter stent platform (Advanced Bifurcation Systems [ABS], Los Angeles, CA, USA).

The mother-daughter stent platform (currently only available in a bare metal version) consists of a mother stent (deployed in the main branch) and a daughter stent (deployed in the side branch), and could be considered as a systematic T-stent strategy (Figure 3). This device, advanced over two wires, is unique because the side branch stent deployment is performed simultaneously with the deployment of the proximal part of the main branch stent14. In theory, this will lead to better alignment of the side branch stent at the ostium without leaving a gap between both stents9. However, clinical experience is very limited, and more studies are needed14. The Tryton stent (currently available in bare metal only) facilitates an inverse culotte technique (according to the MADS classification32), in which the side branch is treated first (Online Figure 1)33,34. The stent is available mounted on a stepped balloon with different proximal and distal diameters, obeying the fractal geometry of the coronary tree21,22,34. Furthermore, the special design of the stent with a minimal amount of metal with large stent cells in the (proximal) main branch zone allows easy delivery of a DES in the main branch without restricting the stent expansion to a certain limit, as seen with the culotte technique (the so-called “napkin-ring effect”)35,36.

The use of the Tryton has been shown to be feasible with a delivery success rate of around 96%37-39. The Tryton IDE trial showed that the use of the Tryton resulted in a predictable result at the side branch in terms of post-procedure in-segment percentage diameter stenosis (Tryton 11.98±9.64% vs. provisional 30.51±17.19%, p<0.001)39. However, the primary clinical non-inferiority endpoint of the Tryton IDE trial was not met due to a numerically higher rate of periprocedural myocardial infarction (MI). This difference in periprocedural MI might be explained by the inclusion of relatively small side branches in the trial (approximately 60% did not meet the inclusion criterion of side branch diameter <2.5 mm). Future studies are needed to confirm that there is no increased risk of periprocedural MI when using this device in sufficiently sized side branches (i.e., >2.5 mm) and to assess whether the device needs a drug coating to improve its efficacy.

Combined use of dedicated bifurcation stents with bioresorbable scaffolds

The use of a bioresorbable scaffold (BRS) as the main branch stent in provisional bifurcation treatment might result in favourable long-term results, especially at the side branch ostium. The mechanism of this potential benefit could be due to the resorption of the jailed side branch struts. The hypothesis is that this would in turn eliminate the potential trigger for late stent thrombosis (ST) and prevent late side branch restenosis caused by the jailed non-apposed side branch struts, as occurs with metallic stents.

However, when a two-stent approach is deemed necessary it has been reported that the currently available BRS could be prone to strut fracture when the scaffold is dilated with an oversized balloon (during fenestration and/or with the POT technique) or when final kissing balloon dilatation is performed using balloons at high pressure40. Our group has tested one of the “hybrid” approaches, combining the Absorb BVS (Abbott Vascular, Santa Rosa, CA, USA) in the main branch with the Tryton dedicated bifurcation stent as side branch treatment. However, the initial results were not favourable enough to recommend this approach being used on a large scale in daily clinical practice41.

Future perspectives

The Tryton IDE trial has made it clear how difficult it is to select appropriately the bifurcation lesions which fulfil the predefined inclusion criteria. Since visual estimation has proved to be inaccurate, future bifurcation trials may base patient eligibility on a core lab QCA analysis confirmation of the angiographic inclusion criteria (or, even better, intravascular ultrasound). Furthermore, more studies such as DEFINITION are needed to evaluate further which bifurcation lesions are “complex” and may benefit from a two-stent approach. Dedicated devices facilitating a two-stent strategy should be compared with a two-stent approach using contemporary DES in these complex bifurcation lesions, whereas dedicated stents facilitating the provisional strategy should be compared with a provisional approach using contemporary DES in the remaining. It is conceivable that dedicated devices can only compete with contemporary, tubular DES if they are at least comparable in terms of strut thickness, polymer biocompatibility, and drug efficacy, so that the specific stent design provides an advantage which will improve procedural and clinical outcomes.

Conclusions

Dedicated bifurcation stents may be helpful to simplify the procedure and to improve clinical outcomes further after both the provisional approach and the two-stent approach to treat bifurcation lesions. More randomised trials comparing these devices with contemporary DES are needed to evaluate their potential benefit in daily clinical practice.

Conflict of interest statement

J. Wykrzykowska has received speaker and/or consultancy fees from Abbott, St. Jude, Tryton Medical, and STENTYS. The other authors have no conflicts of interest to declare.

Online Figure 1. Two dedicated bifurcation devices which facilitate the two-stent approach: the mother-daughter stent platform (Advanced Bifurcation Systems [ABS], Los Angeles, CA, USA) (A-D) and the Tryton Side Branch Stent™ (Tryton Medical, Inc., Durham, NC, USA) (E-H). A) Positioning of the mother-daughter stent platform with proximal alignment of the daughter balloon catheter with the mother balloon catheter. B) Inflation of the daughter catheter. Note that not only the daughter stent is deployed, but also the proximal part of the mother stent is deployed by the proximal part of the daughter balloon catheter. This will, in theory, prevent the occurrence of gap formation at the side branch ostium, which often occurs when conventional stents are used. C) Subsequent deployment of the mother stent by inflating the mother balloon. D) Final kissing balloon dilation by inflating both mother and daughter balloons simultaneously, without the need for rewiring or advancing additional balloons. E) Positioning of the Tryton stent, after wiring both branches, by using the two middle markers on the delivery system. F) Inflation of the Tryton stent (note the stepped delivery balloon). G) Deployment of a conventional main branch stent (after POT, after wiring of the distal main branch and after removal of the “trapped’” main branch wire). H) After side branch rewiring, final kissing balloon inflation.


References

Volume 11 Supplement V
May 19, 2015
Volume 11 Supplement V
View full issue


Key metrics

On the same subject

Editorial

10.4244/EIJ-E-23-00052 Mar 18, 2024
Comparative preclinical assessment of drug-coated balloons: a blessing and a curse for clinical translation
Joner M and Wild L
free

Debate

10.4244/EIJ-E-24-00005 Mar 18, 2024
Ischaemic and viability testing for guiding PCI are overrated: pros and cons
McEntegart M et al
free

Original Research

10.4244/EIJ-D-23-00783 Mar 18, 2024
Redo-TAVI with the ACURATE neo2 and Prime XL for balloon-expandable transcatheter heart valve failure
Meier D et al
Trending articles
281.53

State-of-the-Art Review

10.4244/EIJ-D-21-00695 Nov 19, 2021
Transcatheter treatment for tricuspid valve disease
Praz F et al
free
243.2

State of the art

10.4244/EIJ-D-21-01117 Sep 20, 2022
Recanalisation of coronary chronic total occlusions
Di Mario C et al
free
208.35

State-of-the-Art Review

10.4244/EIJ-D-21-01034 Jun 3, 2022
Management of in-stent restenosis
Alfonso F et al
free
168.7

Translational research

10.4244/EIJ-D-21-00824 May 15, 2022
Bench test and in vivo evaluation of longitudinal stent deformation during proximal optimisation
Toth GG et al
free
167.05

Expert review

10.4244/EIJ-D-21-00690 May 15, 2022
Crush techniques for percutaneous coronary intervention of bifurcation lesions
Moroni F et al
free
151.03

State-of-the-Art

10.4244/EIJ-D-22-00776 Apr 3, 2023
Computed tomographic angiography in coronary artery disease
Serruys PW et al
free
118

Translational research

10.4244/EIJ-D-22-00718 Jun 5, 2023
Preclinical evaluation of the degradation kinetics of third-generation resorbable magnesium scaffolds
Seguchi M et al
110.35

Viewpoint

10.4244/EIJ-E-22-00007 May 15, 2022
TAVI at 20: how a crazy idea led to a clinical revolution
Eltchaninoff H et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 6.2
2022 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2023)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved